ALNY - CIK 0001178670
ALNYLAM PHARMACEUTICALS, INC. trades as ALNY and has a market capitalization of $38.62 B, making it the #396 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.71B, up 65.2% from the prior year and net income of $313.75M. This page tracks ALNYLAM PHARMACEUTICALS, INC. through 1,651 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years ALNYLAM PHARMACEUTICALS, INC.'s revenue grew from $47.16M to $3.71B, a compound annual growth rate of 62.4%. Net profit margin expanded from -869.6% to 8.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
| Insider trade | 4 | 2026-04-07 |
The largest companies sharing ALNYLAM PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a market capitalization of $38.62 B as of 2026-06-10, ranking #396 among US-listed companies.
ALNYLAM PHARMACEUTICALS, INC. reported revenue of $3.71B for fiscal year 2025, an increase of 65.2% year over year.
Yes. ALNYLAM PHARMACEUTICALS, INC. reported net income of $313.75M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.